Senior Management

  Anthony Giovinazzo Dr. Albert Agro Dr. Thierry Bilbault
Andrew Williams

Dr. Thierry Bilbault

Chief Scientific Officer and Executive Vice President CMC

Dr. Thierry Bilbault is Cynapsus' Chief Scientific Officer and Executive Vice President, CMC. He is a global pharmaceutical development and manufacturing operations leader with over 20 years of experience in the evaluation, development, partnering, transfer and manufacturing of API and Drugs (Rx, Generics, Switches, OTC) and Medical Device products. Dr. Bilbault has been involved with bringing more than 50 products to the market, including over 10 U.S. New Drug Applications. He joined Cynapsus from Galderma Pharma S.A. (part of Nestle Skin Health S.A.), where he has been a Technical and Industrial Development Director. Prior to Galderma, he served as Vice President New Technology and Product Innovation at Novartis, and held several product development leadership roles at Pfizer and Alcon Laboratories. Dr. Bilbault is a hands-on technical expert in product and manufacturing technology screening and implementation, drug delivery optimization, process scale-up, product/packaging validation, and technology transfer of innovative and conventional solid (including oral/thin films, IR, SR, DR tablets, capsules, ODT, chews, lozenges, gum etc.), topical and liquid drug products.

At Galderma, as Technical Director, Dr. Bilbault led the Engineering/SHE, QA & Regulatory Compliance, API and Strategic Raw Materials Technical Management, Portfolio Management and Industrial Development corporate and operational teams. He led the industrialization and transfer initiatives for Galderma Manufacturing & Technical Operations Division internal and third-party sites to develop capacity, support plant network strategies and generate the CMC data for global registration dossiers.

At Novartis, Dr. Bilbault led and managed the teams responsible for the search, evaluation and development of new technologies and dosage forms applicable to Smoking Cessation, Cough Cold Allergy, Dermatology, NSAIDs and GI. He also led intellectual property creation, new product idea generation and idea qualification for development across all brands and regions. He developed the growth strategy and built the organization supporting the 5 pillars of growth: Centers of Technology Excellence (Thin Films Strips, Oral and Derma/Transdermal technology platforms), creation of Alliance Management function, implementation of New Technology Search paradigm, initiation of monthly Intellectual Property Assessment Meetings and creation of Sensory Guidance and Evaluation and Packaging Innovation competencies. He led the global teams and launch activities for major brands including Triaminic, Theraflu and Gas-X Thin Strips.

At Pfizer CHC, Dr. Bilbault led the co-development of several multi-disciplinary teams on 85 active projects for Oral Care, Skin Care, Oral Thin Films and Patches, Eye Care, Upper Respiratory, New Technology Platforms, and Nicotine Replacement categories and was responsible for the technology due diligence, technical transfer and worldwide launch activities for Pfizer Consumer Healthcare OTC/NDA/Medical devices and cosmetic products. He developed with Pfizer Global Manufacturing (PGM) leadership, global internal/contract manufacturing sites, and Marketing/Sales operations global commercialization strategies, including sourcing decisions, internal capacity adjustments and contingency planning. At Pfizer, Dr. Bilbault developed and/or led the global launch activities for more than 30 products, including Listerine PocketPacks and Listerine Whitening Quick Dissolving thin films.

Dr. Bilbault holds a MS in Biological Engineering from CUST Engineering (Clermont-Ferrand, France), and was granted a Ph.D. in Molecular and Cellular Biology from Clermont-Ferrand II (Clermont-Ferrand, France).

Horizonatal Rule
About CynapsusLine SeperationAPL-130277 ProductLine SeperationParkinson's DiseaseLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2015, Cynapsus Therapeutics Inc.
All rights reserved.

Traded on